Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(3.94)
# 466
Out of 4,814 analysts
224
Total ratings
33.5%
Success rate
14.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $69.95 | +75.84% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $3 | $0.19 | +1,462.50% | 4 | Mar 26, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $11.25 | +166.67% | 5 | Mar 20, 2025 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | $163 | $53.79 | +203.03% | 15 | Mar 19, 2025 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $2.31 | +203.69% | 10 | Mar 18, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $99 → $132 | $42.24 | +212.50% | 8 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $7.16 | +249.16% | 1 | Mar 12, 2025 | |
| ADMA ADMA Biologics | Reiterates: Overweight | $25 | $21.31 | +17.32% | 9 | Mar 4, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $118 | $35.64 | +231.09% | 18 | Feb 26, 2025 | |
| SUPN Supernus Pharmaceuticals | Reiterates: Neutral | $36 | $30.78 | +16.96% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $113 | $47.45 | +138.15% | 18 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $18.29 | +266.32% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.83 | +207.69% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $6.07 | +378.15% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.49 | +584.10% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.96 | +729.96% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $13.00 | +346.15% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $25 | $16.88 | +48.10% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.12 | +418.87% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.25 | +460.00% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.84 | +271.90% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.44 | +875.61% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.66 | +683.13% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.06 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.21 | +1,642.74% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.42 | +1,344.04% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.45 | +1,279.31% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.59 | +786.70% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.27 | +70,766.14% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.72 | +5,594.44% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.43 | +16,360.91% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.89 | +9,472.07% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,500 | $0.32 | +1,086,519.06% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.89 | +2,956.03% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.10 | +3,990.91% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.65 | +1,584.02% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.16 | +5,072.41% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.95 | +9,373.68% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.34 | +187,959.70% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.53 | +30,151.47% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $69.95
Upside: +75.84%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $3
Current: $0.19
Upside: +1,462.50%
Capricor Therapeutics
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $11.25
Upside: +166.67%
Sarepta Therapeutics
Mar 19, 2025
Reiterates: Overweight
Price Target: $163
Current: $53.79
Upside: +203.03%
Mereo BioPharma Group
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.31
Upside: +203.69%
Disc Medicine
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $42.24
Upside: +212.50%
Zevra Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: $25
Current: $7.16
Upside: +249.16%
ADMA Biologics
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $21.31
Upside: +17.32%
Ultragenyx Pharmaceutical
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $35.64
Upside: +231.09%
Supernus Pharmaceuticals
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $30.78
Upside: +16.96%
Feb 3, 2025
Maintains: Overweight
Price Target: $76 → $113
Current: $47.45
Upside: +138.15%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $18.29
Upside: +266.32%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.83
Upside: +207.69%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $6.07
Upside: +378.15%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $2.49
Upside: +584.10%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.96
Upside: +729.96%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $13.00
Upside: +346.15%
Dec 10, 2024
Maintains: Neutral
Price Target: $15 → $25
Current: $16.88
Upside: +48.10%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.12
Upside: +418.87%
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.25
Upside: +460.00%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.84
Upside: +271.90%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.44
Upside: +875.61%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.66
Upside: +683.13%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.06
Upside: -
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.21
Upside: +1,642.74%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.42
Upside: +1,344.04%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.45
Upside: +1,279.31%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.59
Upside: +786.70%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.27
Upside: +70,766.14%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.72
Upside: +5,594.44%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.43
Upside: +16,360.91%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.89
Upside: +9,472.07%
Feb 28, 2022
Initiates: Overweight
Price Target: $3,500
Current: $0.32
Upside: +1,086,519.06%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $5.89
Upside: +2,956.03%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.10
Upside: +3,990.91%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.65
Upside: +1,584.02%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.16
Upside: +5,072.41%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.95
Upside: +9,373.68%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.34
Upside: +187,959.70%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.53
Upside: +30,151.47%